Execs On The Move: June 1–5, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - June 11, 2026

New EU Packaging Rules: What Consumer Healthcare Companies Need To Know
Squire Patton Boggs counsel Manon Ombredane and EUROPEN senior public affairs manager Marzia Scopelliti talked industry through the practical implications of the EU’s Packaging and Packaging Waste Regulation at the 62nd AESGP Annual Meeting in Berlin.
HBW Insight - June 11, 2026

Execs On The Move: May 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - June 11, 2026

Executives On The Move: Four CEOs And Five CFOs Among This Week’s Changes
Recent moves in the industry include changes at the top at AiRNA Pharmaceuticals and Bullfrog AI, plus Genovyn gets a new CSO from Eli Lilly.
Scrip - June 11, 2026

US Consumer Health People Moves: Seed Health, SDC Nutrition, AHPA, HRG, Hello, More
Seed Health adds marketing chief; SDC has new CEO, facility; Wilson Is AHPA VP for association programs; HRG president, majority owner marks 40 years; actress puts on “aura” for hello; and Vitamin Angels names chief financial, administrative officer.
HBW Insight - June 11, 2026

US Drug Shortages Ease But Discontinuations Surge, Asia Supply Chain Risks Run Deep
The US saw fewer drug shortages in 2025, but surging product discontinuations and a supply chain tethered to China and India for key starting materials and also the EU for APIs highlight vulnerabilities, especially amid geopolitical turbulence.
Scrip - June 11, 2026

Positive Del-Brax Biomarker Data Offers Early Support For Novartis’s Avidity Bet
With Phase III already underway, the focus now shifts from biomarker activity to whether del-brax can deliver meaningful functional benefits for FSHD patients.
Scrip - June 11, 2026

Orionis Back In Novartis’s Orbit With New Molecular Glue Deal
Deal Snapshot: Novartis's second Orionis collaboration targets molecular glue drugs for challenging targets and carries a deal value of $40m upfront and up to $1.4bn in milestones plus royalties.
Scrip - June 11, 2026

Vague AI Literacy Requirements For Medtech Signal A Problem In Europe
Watered-down EU training obligations and growing evidence of automation bias are shifting liability risk toward device makers, experts have warned.
Medtech Insight - June 11, 2026

Lupin Launches Continue To Multiply
As a busy Q2 continues, Lupin has received three notable approvals across its generic and biosimilars portfolios, all within the past two weeks.
Generics Bulletin - June 11, 2026

Nexus Faces Five Year Wait On Injectable Minocycline
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Generics Bulletin - June 11, 2026

Apotex Upsizes IPO As Investors Back Canadian Pharma
Apotex has upsized its planned TSX IPO to around C$1.3bn, with the listing set to become the exchange’s largest-ever life sciences float while giving existing shareholders a partial exit and leaving SK Capital firmly in control.
Generics Bulletin - June 11, 2026

Ambitious Oriva Wants To Be Key Player In Women’s Health
Emerging Company Profile: The Spanish biotech’s new CEO Agnès Arbat tells Scrip that the firm’s two assets for gynecological disease have the potential to dramatically impact the space.
Scrip - June 11, 2026

Early-Stage Medtech Funding Is Contracting – And The Pipeline Will Feel It
Early-stage medtech funding is contracting sharply, while capital has piled into later-stage, de-risked assets. Three investors at the front lines of that gap explain what it takes to survive it, and what happens to the pipeline if fewer companies do.
In Vivo - June 11, 2026

Endogene.bio CEO On A Menstrual-Blood Test For Endometriosis
A methylation sequencing assay on uncultured menstrual stem cells hit 79% sensitivity and 83% specificity across two independent sites — early data endogene.bio CEO María Teresa Pérez Zaballos frames as a route to molecular stratification, not just diagnosis.
Medtech Insight - June 11, 2026

New York Setting Limits For Mercury In Cosmetics, Personal Care
New York's DEC is moving to restrict mercury in cosmetics — particularly skin-lightening products — while also clarifying how companies must demonstrate compliance with the state's existing 1,4-dioxane limits.
HBW Insight - June 11, 2026